Zydelig (Idelalisib)

Brand Options

arrow pointer

Brand Name : Zydelig

Marketing Authorization Holder : Gilead Sciences

Prescription Required

 
 
No Generic Medicine available for this medicine.

Product Details

Zydelig

Save over 40% with Zydelig from Europe.

Non-english packaging is often present for European medicines- English label and English insert included. Plan in advance - allow us 7 days to ship this brand name medicine

According to the European Medicines Agency, brand name Zydelig originating from Europe is manufactured at the following site(s):Gilead Sciences Ireland UC IDA Business & Technology Park Carrigtohill County Cork Ireland

Information about Zydelig (Idelalisib)

Zydelig is a prescription medication containing Idelalisib, an oral kinase inhibitor used to treat certain types of cancers. It works by targeting and inhibiting specific enzymes (phosphoinositide 3-kinase or PI3K) that are involved in the growth and survival of cancerous cells. Zydelig is primarily used for the treatment of certain hematologic (blood-related) cancers, such as chronic lymphocytic leukemia (CLL) and follicular lymphoma.

Product Highlights

  • Zydelig is primarily used for the treatment of:
  • Zydelig is used in combination with other medications for patients with relapsed or refractory CLL.
  • Zydelig is used for patients with relapsed or refractory follicular lymphoma who have received at least two prior therapies.
  • This condition, which is closely related to CLL, can also be treated with Zydelig when relapsed or refractory.

Key Ingredient

  • Idelalisib

Key Benefits

  • Zydelig targets specific pathways in cancer cells, offering a more focused and potentially less toxic treatment option compared to traditional chemotherapy.
  • It is shown to improve progression-free survival and overall treatment outcomes for patients with certain types of hematologic cancers, particularly in cases that have not responded to other therapies.
  • Zydelig is taken as a pill, which makes it more convenient for patients compared to intravenous chemotherapy treatments.
  • For many patients, Zydelig is easier to tolerate than more aggressive treatments, offering a more manageable option for those with recurrent or advanced cancers.

Direction of Use

  • The typical starting dose for Zydelig is 150 mg orally twice daily (morning and evening). The dosage may vary based on the patient's condition and response to treatment, as well as the combination with other drugs.
  • Zydelig can be taken with or without food.
  • If you miss a dose of Zydelig, take it as soon as you remember unless it is almost time for your next dose. Do not take two doses at once to compensate for a missed dose. 
  • Take Zydelig at the same time every day to maintain consistent levels in your bloodstream.

Safety Concerns

  • Common side effects include diarrhea, fatigue, fever, nausea, and liver enzyme abnormalities. Some patients may experience more severe side effects such as infections, gastrointestinal problems, and lung issues.
  • Zydelig can increase the risk of infections, including serious ones like pneumonia, fungal infections, or hepatitis B reactivation. Close monitoring for signs of infection is necessary during treatment.
  • Liver problems (such as hepatitis, liver failure) are a known risk with Zydelig. Liver function should be regularly monitored with blood tests.
  • Some patients may develop severe lung problems (interstitial lung disease or pneumonitis), which can be fatal. Seek immediate medical attention if you experience difficulty breathing, cough, or fever.
  • Diarrhea and colitis (inflammation of the colon) are common side effects. Prolonged or severe diarrhea can be dangerous and may require discontinuing the medication temporarily.
  • Zydelig may cause low blood cell counts (e.g., neutropenia), so regular blood tests are essential.
  • Zydelig should not be used during pregnancy as it can harm a developing fetus. It is unknown if idelalisib passes into breast milk, so breastfeeding while taking this medication is not recommended.

Avoid Zydelig (Idelalisib) If

  • You are allergic to Idelalisib or any ingredients in Zydelig.
  • You have active or uncontrolled infections.
  • You have liver problems or a history of hepatitis B or C.
  • You are pregnant, intending to become pregnant, or currently breastfeeding. 
  • You have a history of lung disease, especially interstitial lung disease or pneumonitis.
  • You are currently taking certain medications that may interact with Zydelig, such as strong CYP3A4 inhibitors or inducers.


Image Image Image Image